- Home
- CHNR vs KZIA Comparison
CHNR vs KZIA Comparison
Compare CHNR & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- KZIA
- Stock Information
- Founded
- CHNR N/A
- KZIA 1994
- Country
- CHNR Hong Kong
- KZIA Australia
- Employees
- CHNR N/A
- KZIA N/A
- Industry
- CHNR Precious Metals
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- CHNR Basic Materials
- KZIA Health Care
- Exchange
- CHNR Nasdaq
- KZIA Nasdaq
- Market Cap
- CHNR 6.1M
- KZIA 6.0M
- IPO Year
- CHNR 1995
- KZIA 1999
- Fundamental
- Price
- CHNR $0.57
- KZIA $0.88
- Analyst Decision
- CHNR
- KZIA Strong Buy
- Analyst Count
- CHNR 0
- KZIA 2
- Target Price
- CHNR N/A
- KZIA $11.50
- AVG Volume (30 Days)
- CHNR 43.9K
- KZIA 5.5M
- Earning Date
- CHNR 01-01-0001
- KZIA 03-26-2025
- Dividend Yield
- CHNR N/A
- KZIA N/A
- EPS Growth
- CHNR N/A
- KZIA N/A
- EPS
- CHNR N/A
- KZIA N/A
- Revenue
- CHNR N/A
- KZIA $1,655,324.00
- Revenue This Year
- CHNR N/A
- KZIA N/A
- Revenue Next Year
- CHNR N/A
- KZIA N/A
- P/E Ratio
- CHNR N/A
- KZIA N/A
- Revenue Growth
- CHNR N/A
- KZIA 248000.00
- 52 Week Low
- CHNR $0.51
- KZIA $0.85
- 52 Week High
- CHNR $1.43
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- CHNR 43.80
- KZIA 29.00
- Support Level
- CHNR $0.55
- KZIA $0.90
- Resistance Level
- CHNR $0.60
- KZIA $1.60
- Average True Range (ATR)
- CHNR 0.03
- KZIA 0.14
- MACD
- CHNR -0.00
- KZIA 0.02
- Stochastic Oscillator
- CHNR 28.57
- KZIA 4.00
About CHNR China Natural Resources Inc.
China Natural Resources Inc is an investment holding company. It principally engaged in the exploration and mining and wastewater treatment businesses in the People's Republic of China. The company has two operating segments: (i) Wastewater treatment segment, which consists of sales of assembled equipment, provision of construction service, and participation in PPP projects as an operator (ii) Exploration and mining segment, which consists of the exploration of lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and the trading of copper ores products. It earns the majority of its revenue from the Wastewater treatment segment.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.